Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029380 · ClinicalTrials.gov registry record · Phase 2
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
A Phase 2 study of Hematopoietic Stem Cell Transplantation and Hematologic Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 15
- Study locations
NCT00029380: Completed Phase 2 study of Hematopoietic Stem Cell Transplantation and Hematologic Diseases, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00029380 is a Phase 2 study of Hematopoietic Stem Cell Transplantation and Hematologic Diseases that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 30 participants, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00029380, a Phase 2 study of Hematopoietic Stem Cell Transplantation and Hematologic Diseases, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study will develop a national cord blood bank for siblings of patients with hemoglobinopathies and thalassemia.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Mycophenolate Mofetil
- DRUG Cyclosporine
- DRUG Sangstat
Study Locations (15)
California
- Children's Hospital Oakland - Oakland
- Children's Hospital, Oakland - Oakland
Florida
- Nemours Children's Clinic - Jacksonville
- University of Miami Batchelor Children's Research Center - Miami
Texas
- University of Texas Southwestern Medical Center - Dallas - Dallas
- Texas Transplant Institute - San Antonio
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Children's Memorial Hospital - Chicago
Louisiana
- Louisiana State University Children's Medical Center - New Orleans
Michigan
- University of Michigan - Ann Arbor
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00029380 record still lists
NCT00029380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 9,789-participant average among 26 other Hematopoietic Stem Cell Transplantation trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Hematopoietic Stem Cell Transplantation appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00029380 lists 15 locations in 12 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT00029380 about?
NCT00029380 is a clinical study titled "Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia". This study will develop a national cord blood bank for siblings of patients with hemoglobinopathies and thalassemia.
What is the current status of trial NCT00029380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-01. Estimated completion is 2006-08.
What conditions does trial NCT00029380 study?
This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplantation, Hematologic Diseases, Anemia, Sickle Cell, Beta-Thalassemia.
What interventions are being tested in trial NCT00029380?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Mycophenolate Mofetil (DRUG), Cyclosporine (DRUG), Sangstat (DRUG).
Who is sponsoring clinical trial NCT00029380?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00029380 being conducted?
This trial has 15 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Stem Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00029380's enrollment target sits among peer trials
30 19th of 26 higher than 7 of 26 other Hematopoietic Stem Cell Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic Stem Cell Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
RECRUITING · Phase 2
-
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
RECRUITING · Phase 2
-
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
RECRUITING · Phase 2
-
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
-
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
COMPLETED · Phase 2
-
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia